Flavour types used by youth and adult tobacco users in wave 2 of the Population Assessment of Tobacco and Health (PATH) Study 2014-2015.


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
07 2020
Historique:
received: 19 11 2018
revised: 18 05 2019
accepted: 28 05 2019
pubmed: 23 9 2019
medline: 18 5 2021
entrez: 23 9 2019
Statut: ppublish

Résumé

Most youth and young adult (YA) tobacco users use flavoured products; however, little is known about specific flavours used. We report flavour types among US tobacco users from the Population Assessment of Tobacco and Health Study, wave 2, 2014-2015. At wave 2, we examined (1) flavour use and type at past 30-day use; (2) new flavoured tobacco product use and type; (3) product-specific flavour patterns across youth (ages 12-17) (n=920), YA (18-24) (n=3726) and adult (25+) (n=10 346) past 30-day and new tobacco users and (4) concordance between self-coded and expert-coded brand flavour type among all adults (18+). Prevalence of flavoured tobacco product use was highest among youth, followed by YA and adult 25+ any tobacco users. Within each age group, flavoured use was greatest among hookah, e-cigarette and snus users. Overall, menthol/mint, fruit and candy/sweet were the most prevalent flavour types at first and past 30-day use across age groups. For past 30-day use, all flavour types except menthol/mint exhibited an inverse age gradient, with more prevalent use among youth and YAs, followed by adults 25+. Prevalence of menthol/mint use was high (over 50% youth, YAs; 76% adults 25+) and exhibited a positive age gradient overall, though the reverse for cigarettes. Brand-categorised and self-reported flavour use measures among adults 18+ were moderately to substantially concordant across most products. Common flavours like menthol/mint, fruit and candy/sweet enhance appeal to young tobacco users. Information on flavour types used by product and age can inform tobacco flavour regulations to addess flavour appeal especially among youth.

Sections du résumé

BACKGROUND
Most youth and young adult (YA) tobacco users use flavoured products; however, little is known about specific flavours used.
METHODS
We report flavour types among US tobacco users from the Population Assessment of Tobacco and Health Study, wave 2, 2014-2015. At wave 2, we examined (1) flavour use and type at past 30-day use; (2) new flavoured tobacco product use and type; (3) product-specific flavour patterns across youth (ages 12-17) (n=920), YA (18-24) (n=3726) and adult (25+) (n=10 346) past 30-day and new tobacco users and (4) concordance between self-coded and expert-coded brand flavour type among all adults (18+).
RESULTS
Prevalence of flavoured tobacco product use was highest among youth, followed by YA and adult 25+ any tobacco users. Within each age group, flavoured use was greatest among hookah, e-cigarette and snus users. Overall, menthol/mint, fruit and candy/sweet were the most prevalent flavour types at first and past 30-day use across age groups. For past 30-day use, all flavour types except menthol/mint exhibited an inverse age gradient, with more prevalent use among youth and YAs, followed by adults 25+. Prevalence of menthol/mint use was high (over 50% youth, YAs; 76% adults 25+) and exhibited a positive age gradient overall, though the reverse for cigarettes. Brand-categorised and self-reported flavour use measures among adults 18+ were moderately to substantially concordant across most products.
CONCLUSIONS
Common flavours like menthol/mint, fruit and candy/sweet enhance appeal to young tobacco users. Information on flavour types used by product and age can inform tobacco flavour regulations to addess flavour appeal especially among youth.

Identifiants

pubmed: 31542778
pii: tobaccocontrol-2018-054852
doi: 10.1136/tobaccocontrol-2018-054852
pmc: PMC7462091
mid: NIHMS1617634
doi:

Substances chimiques

Flavoring Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

432-446

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: MC has received grant funding from Pfizer, Inc, to study the impact of a hospital-based tobacco cessation intervention. MC also receives funding as an expert witness in litigation filed against the tobacco industry. No competing interests were reported by the other authors of this paper.

Références

Tob Control. 2016 Nov;25(Suppl 2):ii4-ii13
pubmed: 27794065
JAMA. 2018 Oct 2;320(13):1379-1380
pubmed: 30285167
Nicotine Tob Res. 2018 May 3;20(6):698-706
pubmed: 28575408
Health Aff (Millwood). 2005 Nov-Dec;24(6):1601-10
pubmed: 16284034
Am J Public Health. 2012 Jul;102(7):1310-2
pubmed: 22594728
Tob Induc Dis. 2009 Dec 18;5(1):16
pubmed: 20021672
Tob Regul Sci. 2015 Apr;1(1):36-41
pubmed: 27853734
Chemosens Percept. 2018 Apr;11(1):1-9
pubmed: 29755639
Am J Public Health. 2008 Sep;98(9):1685-92
pubmed: 18633084
Tob Control. 2015 Jul;24(4):389-94
pubmed: 24721967
Tob Control. 2016 Jan;25(1):66-74
pubmed: 25354674
Tob Induc Dis. 2014 Nov 28;12(1):22
pubmed: 25484852
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
MMWR Morb Mortal Wkly Rep. 2015 Oct 02;64(38):1066-70
pubmed: 26421418
Time. 2002 Dec 16;160(25):85
pubmed: 12510477
MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1276-1277
pubmed: 30439875
Tob Control. 2015 Jan;24(1):28-37
pubmed: 23997070
Tob Control. 2016 Nov;25(Suppl 2):ii14-ii20
pubmed: 27729565
Tob Control. 2016 Nov;25(Suppl 2):ii32-ii39
pubmed: 27633764
Tob Control. 2015 Dec;24(e4):e246-50
pubmed: 24652459
Healthy People 2010 Stat Notes. 2002 Jul;(24):1-12
pubmed: 12117004
Nicotine Tob Res. 2008 Jul;10(7):1209-14
pubmed: 18629731
Tob Control. 2017 Mar;26(2):235-236
pubmed: 27052097
Nicotine Tob Res. 2015 Oct;17(10):1279-83
pubmed: 25542918
Nicotine Tob Res. 2014 Sep;16(9):1255-65
pubmed: 24984878
Tob Control. 2016 Nov;25(Suppl 2):ii62-ii66
pubmed: 27633762
J Adolesc Health. 2016 Sep;59(3):365-367
pubmed: 27422395
JAMA. 2015 Nov 3;314(17):1871-3
pubmed: 26502219
Prev Chronic Dis. 2018 Aug 23;15:E105
pubmed: 30148426
Tob Control. 2016 Sep;25(5):605-6
pubmed: 26427526
Tob Control. 2018 Mar;27(2):170-176
pubmed: 28400490
Tob Control. 2004 Sep;13(3):211-2
pubmed: 15333865
Tob Control. 2011 May;20 Suppl 2:ii37-43
pubmed: 21504930
Nicotine Tob Res. 2015 Oct;17(10):1255-62
pubmed: 25566782
PLoS One. 2018 Apr 19;13(4):e0196236
pubmed: 29672604
Am J Prev Med. 2012 Jan;42(1):29-36
pubmed: 22176843
Health Place. 2018 Sep;53:62-70
pubmed: 30055469
Tob Control. 2017 Nov;26(6):709-719
pubmed: 27872344
Am J Prev Med. 2017 Aug;53(2):139-151
pubmed: 28318902
Am J Prev Med. 2013 Apr;44(4):388-391
pubmed: 23498105
J Adolesc Health. 2014 Jan;54(1):40-6
pubmed: 24161587
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Int J Environ Res Public Health. 2018 Feb 11;15(2):
pubmed: 29439464
Tob Control. 2017 Jul;26(4):471-475
pubmed: 27543562
Nicotine Tob Res. 2013 Feb;15(2):608-14
pubmed: 22927687
Nicotine Tob Res. 2010 Dec;12 Suppl 2:S147-53
pubmed: 21177371

Auteurs

Shyanika W Rose (SW)

Truth Initiative Schroeder Institute, Washington, DC, USA s.rose@uky.edu.

Amanda L Johnson (AL)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.

Allison M Glasser (AM)

Truth Initiative Schroeder Institute, Washington, DC, USA.

Andrea C Villanti (AC)

Truth Initiative Schroeder Institute, Washington, DC, USA.
Vermont Center on Behavior and Health, Department of Psychiatry, University of Vermont, Burlington, Vermont, USA.

Bridget K Ambrose (BK)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.

Kevin Conway (K)

Division of Epidemiology, Services, and Prevention Branch, National Institute on Drug Abuse, Bethesda, Maryland, USA.

K Michael Cummings (KM)

Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.

Cassandra A Stanton (CA)

Westat Inc, Rockville, Maryland, USA.
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.

Cristine Delnevo (C)

Center for Tobacco Studies, School of Public Health, Rutgers University, Piscataway, New Jersey, USA.

Olivia A Wackowski (OA)

Center for Tobacco Studies, School of Public Health, Rutgers University, Piscataway, New Jersey, USA.

Kathryn C Edwards (KC)

Westat Inc, Rockville, Maryland, USA.

Shari P Feirman (SP)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.

Maansi Bansal-Travers (M)

Health Behavior, Roswell Park Cancer Institute, Buffalo, New York, USA.

Jennifer Bernat (J)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.

Enver Holder-Hayes (E)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.

Victoria Green (V)

Division of Epidemiology, Services, and Prevention Branch, National Institute on Drug Abuse, Bethesda, Maryland, USA.
Kelly Government Solutions, Rockville, Maryland, USA.

Marushka L Silveira (ML)

Division of Epidemiology, Services, and Prevention Branch, National Institute on Drug Abuse, Bethesda, Maryland, USA.
Kelly Government Solutions, Rockville, Maryland, USA.

Yitong Zhou (Y)

Truth Initiative Schroeder Institute, Washington, DC, USA.

Haneen Abudayyeh (H)

Truth Initiative Schroeder Institute, Washington, DC, USA.

Andrew Hyland (A)

Health Behavior, Roswell Park Cancer Institute, Buffalo, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH